Corona Remedies is set to raise ₹655.4 crore via an offer for sale. The company focuses on specialist doctors, driving faster revenue growth than the Indian pharmaceutical market. Its sales grew by 13.6% compared to the market’s 7.9%. Revenue and net profit have shown strong annual growth. Investors with a high-risk appetite can consider this IPO for the long term.
FPIs’ outflow nears Rs 33,000 crore in May on weaker rupee
However, the trend reversed in March, when foreign investors pulled out a record Rs 1.17 lakh crore. The selling continued in April with net outflows